Teclistamab in Elderly Patients With Relapsed/Refractory Multiple Myeloma: A Subgroup Analysis of the French RetrosTECtive Cohort

Le résumé fourni par la source

Introduction: Real-world data on teclistamab in relapsed or refractory multiple myeloma (R/R MM), particularly in elderly patients, remain limited. Methods: cohort. Among 303 patients, 90 were aged ≥ 75 years and compared with 213 younger patients. Results: Elderly patients had fewer high-risk cytogenetic abnormalities and a longer disease history. Remarkably, teclistamab appeared more effective in this population, with 74% achieving at least a very good partial response, compared with 62% of younger patients. Median progression-free survival was 15.1 months in the elderly cohort versus 12.4 months in younger patients. Conclusion: This improved efficacy did not come at the cost of increased toxicity: adverse event rates were comparable, although older patients more frequently received prophylactic measures. These findings support teclistamab as a safe and effective therapeutic option for geriatric patients with R/R MM. Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.